Watson Pharmaceuticals
This article was originally published in The Tan Sheet
Executive Summary
Introducing nicotine polacrilex gum in 2 mg and 4 mg strengths this summer following FDA approval of the products March 15 and March 19, respectively. The delay of the launch reflects the company's need for time to position its first OTC product, Watson says. The reference drug is SmithKline Beecham's Nicorette, which lost Waxman/Hatch marketing exclusivity Feb. 9 ("The Tan Sheet" Jan. 18, p. 4)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning